Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.

Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, Javier Martin-Broto, Antonio Lopez Pousa, Giovanni Grignani, Umberto Basso, Jean Yves Blay, Oscar Tendero, Robert Diaz Beveridge, Virginia Ferraresi, Iwona Lugowska, Domenico Franco Merlo, Valeria Fontana, Emanuela Marchesi, Davide Maria Donati, Elena Palassini, Emanuela Palmerini, Rita De Sanctis, Carlo MorosiSilvia Stacchiotti, Silvia Bague, Jean Michelle Coindre, Angelo P. Dei Tos, Piero Picci, Paolo Bruzzi, Paolo Giovanni Casali

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.'. Together they form a unique fingerprint.

Medicine & Life Sciences